Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
Status:
Completed
Trial end date:
2021-07-13
Target enrollment:
Participant gender:
Summary
This study will test PANO in combination with tacrolimus/sirolimus (TAC/SIR) for acute GVHD
prevention. The purpose of this study is to determine if Panobinostat (PANO) when used in
combination with sirolimus and tacrolimus will help reduce the incidence of Graft-vs-host
disease (GVHD).
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute